UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

The New England journal of medicine, 2020-05, Vol.382 (19), p.1787-1799

2020

Volltextzugriff (PDF)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Nature communications, 2020-01, Vol.11 (1), p.222-14, Article 222

2020

Volltextzugriff (PDF)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

The Lancet (British edition), 2020-05, Vol.395 (10238), p.1695-1704

2020

Volltextzugriff (PDF)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet (British edition), 2020-10, Vol.396 (10259), p.1345-1352

2020

Volltextzugriff (PDF)

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Antiviral research, 2020-06, Vol.178, p.104786-104786, Article 104786

2020

Volltextzugriff (PDF)

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option

Journal of medical virology, 2020-06, Vol.92 (6), p.556-563

2020

Volltextzugriff (PDF)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

The Journal of infection, 2020-07, Vol.81 (1), p.e21-e23

2020

Volltextzugriff (PDF)

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

Biochemistry (Easton), 2020-05, Vol.59 (18), p.1769-1779

2020

Volltextzugriff (PDF)

EFFECTS OF COMBINATION OF ETHANOL WITH RITONAVIR, LOPINAVIR OR DARUNAVIR ON EXPRESSION AND LOCALIZATION OF THE ER-ASSOCIATED SET PROTEIN AND INFECTION OF HIV-1 PSEUDOVIRUS IN PRIMARY HUMAN CELLS

Journal of acquired immune deficiency syndromes (1999), 2024-05

2024

Volltextzugriff (PDF)

SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

Current medicinal chemistry, 2020-01, Vol.27 (27), p.4536-4541

2020

Volltextzugriff (PDF)

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

International journal of infectious diseases, 2020-06, Vol.95, p.183-191

2020

Volltextzugriff (PDF)

A Trial of Lopinavir-Ritonavir in Covid-19. Reply

The New England journal of medicine, 2020-05, Vol.382 (21), p.e68-e68

2020

Volltextzugriff (PDF)

Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

Journal of Korean medical science, 2020-02, Vol.35 (6)

2020

Volltextzugriff (PDF)

Treatment With Lopinavir/Ritonavir or Interferon- beta 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

The Journal of infectious diseases, 2015-12, Vol.212 (12), p.1904-1913

2015

Volltextzugriff (PDF)

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

Journal of biomolecular structure & dynamics, 2021-04, Vol.39 (7), p.2673-2678

2021

Volltextzugriff (PDF)

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

The Lancet infectious diseases, 2019-03, Vol.19 (3), p.253-264

2019

Volltextzugriff (PDF)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Clinical microbiology and infection, 2021-12, Vol.27 (12), p.1826-1837

2021

Volltextzugriff (PDF)

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

The European respiratory journal, 2020-07, Vol.56 (1), p.2000799

2020

Volltextzugriff (PDF)

A novel LOPCOW‐DOBI multi‐criteria sustainability performance assessment methodology: An application in developing country banking sector

Omega (Oxford), 2022-10, Vol.112, p.102690, Article 102690

2022

Volltextzugriff (PDF)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Intensive care medicine, 2021-08, Vol.47 (8), p.867-886

2021

Volltextzugriff (PDF)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2

Biomedicine & pharmacotherapy, 2020-11, Vol.131, p.110668-110668, Article 110668

2020

Volltextzugriff (PDF)

Combining LOPIT with differential ultracentrifugation for high-resolution spatial proteomics

Nature communications, 2019-01, Vol.10 (1), p.331-331, Article 331

2019

Volltextzugriff (PDF)

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

European review for medical and pharmacological sciences, 2020-03, Vol.24 (6), p.3390

2020

Volltextzugriff (PDF)

Chitosan oligosaccharides attenuate loperamide-induced constipation through regulation of gut microbiota in mice

Carbohydrate polymers, 2021-02, Vol.253, p.117218, Article 117218

2021

Volltextzugriff (PDF)

1 – 25 von 6.002.191

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.443.777)
Mit Volltextzugriff
(4.956.621)

Publikationsform

Artikel
(5.019.736)
Dissertationen
(287.062)
Buchkapitel
(186.721)
Zeitungsartikel
(142.768)
magazinearticle
(140.517)
Tagungsberichte
(69.648)
Reviews
(60.893)
Newsletter-Artikel
(39.661)
Referenzeintrag
(29.215)
Berichte
(11.622)
Bücher
(11.170)
Texte
(2.553)
Datensätze
(381)
Webseiten
(201)
government_documents
(14)
market_researchs
(12)
Sonstige
(5)
Bilder
(3)
Zeitschriften
(3)
videos
(3)

15 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(5.371.047)
Spanisch
(358.776)
Portugiesisch
(239.824)
Deutsch
(104.689)
Französisch
(46.516)
Japanisch
(14.404)
Norwegisch
(10.307)
Türkisch
(7.320)
Italienisch
(6.566)
Katalanisch
(4.880)
Russisch
(4.675)
Bokmål, Norwegian; Norwegian Bokmål
(4.434)
Chinesisch
(3.934)
Polnisch
(2.486)
Niederländisch
(1.904)
Ungarisch
(1.522)
Litauisch
(1.318)
Serbian
(1.209)
Croatian
(1.058)
Koreanisch
(933)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.275.906)
Life Sciences & Biomedicine
(2.181.185)
Humans
(956.779)
Physical Sciences
(795.570)
Technology
(699.396)
Female
(478.785)
Animals
(465.995)
Male
(465.736)
Chemistry
(437.021)
Engineering
(341.759)
Social Sciences
(299.312)
Biological And Medical Sciences
(287.070)
Adult
(246.823)
Environmental Sciences & Ecology
(241.068)
Biochemistry & Molecular Biology
(238.221)
Materials Science
(232.102)
Physics
(230.596)
Middle Aged
(229.013)
Science & Technology - Other Topics
(208.778)
Environmental Sciences
(195.346)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(2.479.575)
EZB Electronic Journals Library
(2.231.781)
MEDLINE
(1.434.091)
Elsevier ScienceDirect Journals Complete
(1.165.234)
IngentaConnect Journals
(1.026.388)
Journals@Ovid
(789.706)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(786.374)
Springer journals
(561.029)
Wiley Blackwell Single Titles
(532.714)
Publisher or Other Site
(465.106)
Wiley Online Library
(399.111)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(350.507)
Nexis Uni
(346.658)
ProQuest Dissertations & Theses A&I
(286.877)
JSTOR
(206.823)
Access via Business Source (EBSCOhost)
(180.300)
Ebook Central Perpetual and DDA
(177.285)
eBooks on EBSCOhost
(170.831)
Taylor & Francis Journals
(150.783)
Taylor & Francis
(141.535)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(50.419)
Nebelspalter
(34.039)
Nebelspalter : Das Humor- Und Satire-Magazin
(32.121)
New York Times
(31.479)
Billboard
(27.434)
International Journal Of Molecular Sciences
(24.398)
Scientific Reports
(22.714)
The New York Times
(21.442)
The Science Of The Total Environment
(16.017)
Pr Newswire
(15.971)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

EFFECTS OF COMBINATION OF ETHANOL WITH RITONAVIR, LOPINAVIR OR DARUNAVIR ON EXPRESSION AND LOCALIZATION OF THE ER-ASSOCIATED SET PROTEIN AND INFECTION OF HIV-1 PSEUDOVIRUS IN PRIMARY HUMAN CELLS

SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

A Trial of Lopinavir-Ritonavir in Covid-19. Reply

Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

Treatment With Lopinavir/Ritonavir or Interferon- beta 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

A novel LOPCOW‐DOBI multi‐criteria sustainability performance assessment methodology: An application in developing country banking sector

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Combining LOPIT with differential ultracentrifugation for high-resolution spatial proteomics

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

Chitosan oligosaccharides attenuate loperamide-induced constipation through regulation of gut microbiota in mice

Suchergebnisse filtern